In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)

Bioorganic and Medicinal Chemistry Letters

Volumn 11, Issue 8, 2001, Pages 1059-1062

  Chauret, Nathalie ^a   Yergey, James A ^a   Brideau, Christine ^a   Friesen, Richard W ^a   Mancini, Joseph ^a   Riendeau, Denis ^a   Silva, José ^a   Styhler, Angela ^a   Trimble, Laird A ^a   Nicoll Griffith, Deborah A ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; ETORICOXIB; ROFECOXIB; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; LIVER CELL; MICROSOME; STRUCTURE ACTIVITY RELATION;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MICROSOMES; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDINES; SULFONES;

EID: 0035938410     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(01)00135-4     Document Type: Article

References (23)